Cite item


To confirm a progress towards the rubella elimination, immunization coverage indicators and the results of serological studies are used. At the same time, the most objective method of assessing collective immunity is a serological examination. The purpose of this work was to compare the results of assessing state of population immunity against rubella virus in the Republic of Belarus and the Russian Federation using various vaccines and different approaches to study organization and cohort selection – screening and monitoring.

2019 laboratory studies to determine IgG antibodies against rubella virus were carried out by ELISA method of the unified enzyme immunoassay system "Ecolab", Russia. The serum study results of 701 subjects aged 2-45 years from all the 7 regions of the Republic of Belarus (screening study) and 55,082 subjects aged 3-49 years (monitoring) from 85 regions of the Russian Federation were analyzed. The results were evaluated in three age groups - children, adults, total cohort by using a threshold level of 83-85% seropositive individuals sufficient to prevent virus transmission.

The antigenic composition of the rubella component in the mono- and complex vaccines respectively used in the Russian Federation and the Republic of Belarus is identical, which allows to compare the state of population immunity against rubella virus therein without taking into account an influence of the vaccine strain.

Studies have shown that while using varying vaccine preparations and approaches to organization of serological examination, both in the Republic of Belarus and the Russian Federation, rubella virus-specific IgG level was detected at rather high level in all age groups comprising more than 90%. The portion of rubella seropositive subjects in entire country was 95.44% in the Republic of Belarus and 97.14% in the Russian Federation. Moreover, the level of specific antibodies remains high, despite the low incidence rate and absence of booster effect in both countries. The mean group antibody concentration in seropositive patients in all age groups was quite high and exceeded the minimum protective concentration (11 IU/ml) by 10 or more times. The data obtained indicate the legitimacy of using a serological study of collective rubella immunity as a routine or seromonitoring as well as periodic or screening investigation.

About the authors

Olga Valentinovna Tsvirkun

G.N. Gabrichevsky research institute for epidemiology and microbiology,
People’s Friendship University.

Author for correspondence.
ORCID iD: 0000-0002-3810-4804

aD. Sc. (Med.), head of epidemiology department,

bassociate professor at the Chair of Infectious Diseases with Courses in Epidemiology and Phthisiology 

Russian Federation

Elena Olegovna Samoilovich

Republican Research and Practical Center for Epidemiology and Microbiology.


cD. Sc. (Med.), Professor, Head of the Laboratory of Vaccine preventable diseases,  


Nina Timofeevna Tikhonova

G.N. Gabrichevsky research institute for epidemiology and microbiology

ORCID iD: 0000-0002-8762-4355

D. Sc. (Biol.), ProfessorChief Researcher of the Cytokine Laboratory

Russian Federation

Alexsandra Georgievna Gerasimova

G.N. Gabrichevsky research institute for epidemiology and microbiology

ORCID iD: 0000-0002-7504-2622

bPh.D.(Med),leading researcher at the Laboratory for the Prevention of Viral Infections

Russian Federation

Natalya Victorovna Turaeva

G.N. Gabrichevsky research institute for epidemiology and microbiology

ORCID iD: 0000-0001-7657-4631

bPh.D.(Med),Head of the Laboratory for the Prevention of Viral Infections

Russian Federation

Marina Anatolievna Ermalovich

Republican Scientific and Practical Center for Epidemiology and Microbiology


cD. Sc. (Med.), Leading researcher, Laboratory of Vaccine preventable diseases 


Galina Valerievna Semeiko

Republican Scientific and Practical Center for Epidemiology and Microbiology


cPh. D. (Biol.), Leading researcher, Laboratory of Vaccine preventable diseases



  1. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году».
  2. Самойлович Е.О. Надзор за вакциноуправляемыми инфекциями в Республике Беларусь: соответствие международным стандартам / Е.О. Самойлович // Здравоохранение. – 2014. – № 6 – С. 7-11.
  3. Самойлович Е.О., Свирчевская Е.Ю.,Ермолович М.А.,
  4. Семейко Г.В.
  5. Популяционный иммунитет к краснухе в Республике Беларусь в 2011 г.// Современные проблемы инфекцион-ной патологии человека: сб. науч. тр. – Электрон. дан. (6,4 Мб). – Минск: РНМБ, 2012. – Вып. 5. – С. 261-264. – 1 электрон. опт. диск (CD-ROM).
  6. Семейко Г.В., Самойлович Е.О., Ермолович М.А., Свирчевская Е.Ю. Краснуха в Республике Беларусь в 2016-2019 гг. // Современные проблемы инфекцион-ной патологии человека: сб. науч. тр. / М-во здравоохр. Респ. Беларусь. РНПЦ эпидемиологии и микробиологии; под ред. В.А. Горбунова. — Минск: СтройМедиаПроект, 2019. – Вып. 12. – С. 74-77.
  7. Таточенко В.К., Озерецковский Н.А. «Вакцинопрофилак-тика-2018», справочник, 13-е издание, расширенное, ООО «МСД Фармасьютикалс». М.,2018, с.268
  8. Bianchi FP, De Nitto S, Stefanizzi P, Larocca AMV, Germinario CA, Tafuri S.//Immunity to rubella: an Italian retrospective cohort study. BMC Public Health. 2019 Nov 8;19(1):1490. doi: 10.1186/s12889-019-7829-3. PMID: 31703651
  9. Borras E, Campins M, Esteve M, Urbiztondo L, Broner S, Bayas JM, et al. //Are healthcare workers immune to rubella? Hum Vaccin Immunother 2014;10 (3):686–91.
  10. Coppeta L, Ferrari C, Iannuzzi I, D'Alessandro I, Balbi O, Pietroiusti A, Trabucco Aurilio M.// Rubella Immunity among Italian Female Healthcare Workers: A Serological Study. Int J Environ Res Public Health. 2020 Oct 30;17(21):7992.doi: 10.3390/ijerph17217992.
  11. Dean A.G., Sullivan K.M., Soe M.M. OpenEpi: open source epidemiologic statistics for public health // http://www. OpenEpi. com. – 2007.
  12. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Goergen KM, Grill DE, Chen MH, Hao L, Icenogle J, Poland GA.Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age. Vaccine. 2020 Jan 29;38(5):1249-1257. doi: 10.1016/j.vaccine.2019.11.004. Epub 2019 Nov 12.
  13. Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef SE. //Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis 2006;43(Suppl 3):S146–50.
  14. Ogawa T, Inoue T, Kasahara K, Konishi M, Mikasa K.//Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study. PLoS One .-2020 Mar 24;15(3):e0230329. doi: 10.1371/journal.pone.0230329. eCollection 2020.PMID: 32208432
  15. Plotkin’s vaccines, edited by Stanley A. Plotkin, Walter A. Orenstein,
  16. Paul A. Offit et al.: Charter 77, Community Protection.
  17. Paul E.M. Fine, Kim Mulholland, J. Anthony Scott, and W. John Edmunds p.2166- 2190, 7th Eddition, Elsevier, 2018
  18. Stephen n crooke , iana h haralambieva , diane e grill , inna g ovsyannikova, richard b kennedy , gregory a poland // Seroprevalence and durability of rubella virus antibodies in a highly immunized population. Vaccine 2019 Jun 27;37(29):3876-3882. doi: 10.1016/j.vaccine.2019.05.049. Epub 2019 May 21.
  19. World Health Organization. Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region. – Copenhagen. - 2013.-19р.
  20. World Health Organization. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome [Electronic resource]. – Geneva, Switzerland: World Health Organization, 2018. Date of access: 20.11.2020.

Supplementary files

There are no supplementary files to display.

Copyright (c) Tsvirkun O.V., Samoilovich E.O., Tikhonova N.T., Gerasimova A.G., Turaeva N.V., Ermalovich M.A., Semeiko G.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies